Skip to main content

Table 3 Effectiveness of 12-week adalimumab treatment in patients with AS stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

Outcome measure No prior ETN/IFX Prior ETN and/or IFX
  (n = 924) (n = 326)
BASDAI (0 to 10)   
   Baseline 6.2 6.5
  5.2, 7.2 5.5, 7.6
   Change, Baseline to week 12 -3.7 -2.5
  -5.1, -1.9 -4.2, -1.0
BASFI (0 to 10)   
   Baseline 5.2 6.0
  3.5, 7.0 4.3, 7.5
   Change, Baseline to week 12 -2.2 -1.3
  -3.9, -0.8 -2.8, -0.1
Patients with peripheral arthritis (SJC ≥ 1) n = 201 n = 80
TJC (0 to 46)   
   Baseline 4 6
  2, 11 3, 14
   Change, Baseline to week 12 -3 -3
  -8, -1 -8, -1
SJC (0 to 44)   
   Baseline 2 2
  1, 4 1, 4
   Change, Baseline to week 12 -2 -1
  -4, -1 -2, -1
Patients with enthesitis (MASES ≥ 1) n = 492 n = 175
MASES (0 to 13)   
   Baseline 5 5
  2, 8 3, 9
   Change, Baseline to week 12 -3 -2
  -5, -1 -5 , -1
  1. Values are expressed as median and quartile 1, quartile 3. AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; ETN, etanercept; IFX, infliximab; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; TJC, tender joint count; TNF, tumor necrosis factor; SJC, swollen joint count.